Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 4/20 | 0.44 |
| ▸ | SLC6A11 | P48066 | 4/20 | 0.40 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.35 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 5/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14062514 | 1.00 | TYMP (0.44) | TYMPSLC6A11SLC6A1MEN1KMT2A | |
| SCHEMBL26077386 | 1.00 | TYMP (0.44) | TYMPSLC6A11SLC6A1MEN1KMT2A | |
| SCHEMBL14063357 | 1.00 | TYMP (0.44) | TYMPSLC6A11SLC6A1MEN1KMT2A | |
| SCHEMBL14062502 | 1.00 | TYMP (0.44) | TYMPSLC6A11SLC6A1MEN1KMT2A | |
| SCHEMBL13255807 | 0.87 | TYMP (0.45) | TYMPSLC6A11SLC6A1MEN1KMT2A | |
| SCHEMBL13329987 | 0.87 | TYMP (0.45) | TYMPSLC6A11SLC6A1MEN1KMT2A | |
| SCHEMBL13374762 | 0.87 | TYMP (0.45) | TYMPSLC6A11SLC6A1MEN1KMT2A | |
| SCHEMBL10423328 | 0.86 | TYMP (0.44) | TYMPSLC6A11SLC6A1MEN1KMT2A | |
| SCHEMBL9212681 | 0.86 | TYMP (0.44) | TYMPSLC6A11SLC6A1MEN1KMT2A | |
| SCHEMBL14387754 | 0.86 | TYMP (0.41) | TYMPSLC6A11SLC6A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943758-B2 | 3′-end nucleoside unit comprising phosphoramidite | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20080221303-A1 | Method for the Preparation of Peptide-Oligonucleotide Conjugates | FRUTAROM LTD. (IL) | 2008-09-11 | — | — | US | disclosed |
| US-20080039620-A1 | 3'-End Nucleoside Unit Comprising Phosphoramidite | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221303-A1 | Method for the Preparation of Peptide-Oligonucleotide Conjugates | VIP, PTMS, SSTR4 | TYMP 232/4885SLC6A11 4171/4885SLC6A1 4285/4885 |
| US-20080039620-A1 | 3'-End Nucleoside Unit Comprising Phosphoramidite | POLR2H, POLN, RNGTT | TYMP 38/4885SLC6A11 4667/4885SLC6A1 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.